🇺🇸 BMRN — BioMarin Pharmaceutical Inc.

Salud Compra
← Volver

Precio actual

55,66 USD

Máx. histórico

149,13

4124 días

Caída desde máximo

-62,68%

Rango 52 semanas

49,26 – 70,98

Variación hoy

-3,10%

Cierre anterior

57,44

Rango de hoy

52,00 – 56,32

Volumen hoy

4.698.487

Peor caída histórica

-90,58%

01/03/2000 → 27/08/2002

Recuperado en 1960 días

Volatilidad anualizada ⓘ

49,11%

Información
Nombre completo
BioMarin Pharmaceutical Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
3.221
PER ⓘ
150,43 (puede no estar actualizado)
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
91,33 USD (puede no estar actualizado)
Primera cotización
26/07/1999
Precio actualizado
hace 21 horas
Sobre la empresa

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; and KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease. The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
01/06/2022 75,32 76,54 72,89 74,37 -1,01% 4,85% 1.381.300
31/05/2022 80,44 80,45 75,05 75,13 -7,21% 6,71% 2.291.900
27/05/2022 79,00 81,20 78,65 80,97 +2,68% 3,23% 659.500
26/05/2022 78,94 79,84 78,36 78,86 -0,09% 1,87% 691.600
25/05/2022 78,57 79,43 77,26 78,93 +0,19% 2,76% 759.300
24/05/2022 80,00 80,34 78,06 78,78 -1,97% 2,85% 932.300
23/05/2022 80,09 81,11 79,23 80,36 +0,80% 2,35% 573.900
20/05/2022 79,76 80,78 78,26 79,72 +0,55% 3,16% 1.114.100
19/05/2022 78,40 80,36 78,11 79,28 +1,41% 2,87% 852.200
18/05/2022 78,30 79,99 77,61 78,18 -1,19% 3,04% 925.800
17/05/2022 77,61 79,33 77,59 79,12 +2,33% 2,24% 1.069.400
16/05/2022 77,65 78,17 76,41 77,32 -0,53% 2,27% 1.082.900
13/05/2022 77,30 78,90 76,90 77,73 +1,77% 2,59% 1.820.100
12/05/2022 75,12 76,47 74,30 76,38 +0,92% 2,89% 1.608.500
11/05/2022 78,56 79,57 75,60 75,68 -4,72% 5,05% 1.610.500
10/05/2022 76,44 80,22 76,00 79,43 +6,45% 5,52% 1.684.500
09/05/2022 78,00 78,48 73,93 74,62 -5,85% 5,83% 1.814.400
06/05/2022 81,00 81,87 78,96 79,26 -3,31% 3,59% 840.900
05/05/2022 84,14 84,30 81,12 81,97 -3,17% 3,78% 822.000
04/05/2022 83,82 84,66 81,31 84,65 +1,35% 4,00% 877.400
03/05/2022 83,13 84,03 82,28 83,52 +0,25% 2,11% 1.334.100
02/05/2022 80,38 83,47 80,36 83,31 +2,41% 3,87% 1.211.900
29/04/2022 81,95 83,61 81,12 81,35 -1,56% 3,04% 1.468.000
28/04/2022 83,79 84,29 78,95 82,64 +2,90% 6,37% 2.196.100
27/04/2022 79,94 81,15 79,50 80,31 +1,29% 2,06% 1.110.700
26/04/2022 80,97 81,95 79,28 79,29 -3,16% 3,30% 919.000
25/04/2022 82,18 82,74 80,74 81,88 +1,71% 2,43% 1.096.000
22/04/2022 80,15 81,01 79,97 80,50 +0,00% 1,30% 919.500
21/04/2022 81,20 82,09 80,05 80,50 -0,14% 2,51% 805.500
20/04/2022 80,52 81,42 79,67 80,61 +0,04% 2,17% 1.244.800